Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Slides:

Advertisements

Similar presentations

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Advertisements

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Dark Blue Horse Three Green Horse Two Red Horse One Purple Horse Four Light Blue Horse Five Orange Horse Six.

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

This PowerPoint document contains the images that you requested. Thank You Copyright Notice All materials on this Site are protected by United States copyright.

Orange Boat 3Purple Boat 4Red Boat 5Yellow Boat 6Green Boat 2Blue Boat 1.

This PowerPoint document contains the images that you requested.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Figure 4 Progression-free survival, according to treatment group

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Blue Boat 1 Green Boat 2 Orange Boat 3 Purple Boat 4 Red Boat 5

Figure 3 Overall survival, according to treatment group

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Erratum Journal of Thoracic Oncology

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Figure 1. CONSORT diagram.

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

(A) Survival curves according to clinical response.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Survival, subsequent therapies, and response.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

This PowerPoint document contains the images that you requested.

Presentation transcript:

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Supplementary <LINK BD >Figure 1 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Supplementary <LINK BD >Figure 1 </LINK>. Progression-free and overall survival in subgroups of patients.1A. Progression-free survival according to gender (blue, female; red, male)1B. Survival according to gender (blue, female; red, male)1C. Progression-free survival in patients with L858R according to gender (blue, female; green, male)1D. Survival according to ECOG PS (blue, PS0; red, PS1; green, PS2)1E. Progression-free survival in patients with L858R according to age (blue, <60; green, 60-70; red, >70)1F. Survival in patients with L858R according to age (blue, <60; green, 60-70; red, >70)1G. Progression-free survival in PS1 patients according to gender (blue, female; green, male)1H. Survival in PS1 patients according to gender (blue, female; green, male)

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Supplementary <LINK BD >Figure 2 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Supplementary <LINK BD >Figure 2.</LINK> Progression-free (2A) and overall (2B) survival according to response (blue, CR; red, PR; brown, SD; green, PD)

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Table 1 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 1 (Supplementary Appendix). Patient characteristics according to gender

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Table 2 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 2 (Supplementary Appendix). Patient characteristics according to smoking history

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Table 3 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 3 (Supplementary Appendix). Patient characteristics according to age

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 7 Table 4 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 4 (Supplementary Appendix). Patient characteristics according to ECOG PS

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 8 Table 5 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 5 (Supplementary Appendix). Patient characteristics according to treatment line

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 9 Table 6 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 6 (Supplementary Appendix). Metastatic sites

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 10 Table 7 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, Table 7 (Supplementary Appendix). Toxicities